Membrane fusogenic nanoparticle‐based HLA‐peptide‐addressing universal T cell receptor‐engineered T (HAUL TCR‐T) cell therapy in solid tumor
Abstract T cell receptor‐engineered T (TCR‐T) cell therapy has demonstrated therapeutic effects in basic research and clinical trials for treating solid tumors. Due to the peptide‐dependent recognition and the human leukocyte antigen (HLA)‐restriction, TCR‐T cell therapy is generally custom designed...
Main Authors: | Ruihan Xu, Qin Wang, Junmeng Zhu, Yuncheng Bei, Yanhong Chu, Zhichen Sun, Shiyao Du, Shujuan Zhou, Naiqing Ding, Fanyan Meng, Baorui Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-11-01
|
Series: | Bioengineering & Translational Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/btm2.10585 |
Similar Items
-
Complex Size and Surface Charge Determine Nucleic Acid Transfer by Fusogenic Liposomes
by: Marco Hoffmann, et al.
Published: (2020-03-01) -
Fusogenic Viruses in Oncolytic Immunotherapy
by: Teresa Krabbe, et al.
Published: (2018-06-01) -
TCR engineered T cells for solid tumor immunotherapy
by: Yikai Zhang, et al.
Published: (2022-06-01) -
Vitamin D Inhibits Myogenic Cell Fusion and Expression of Fusogenic Genes
by: Tohru Hosoyama, et al.
Published: (2020-07-01) -
Structural basis of the TCR-pHLA complex provides insights into the unconventional recognition of CDR3β in TCR cross-reactivity and alloreactivity
by: Dan San, et al.
Published: (2023-02-01)